Early access
Sign in
Not yet taking people in NorwayPhase 2

Measuring Brain Fluid Clearance to Tailor Spinal Chemotherapy in Teens With Leukemia or Lymphoma

Estimates brain fluid clearance in teens receiving chemotherapy into the spinal fluid.

Key facts

Who runs it
Oslo University Hospital HF
Where
Oslo, NorwaySee the site
Registry title
Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients
Status
Not yet recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
1 Sept 2026
Expected to end
31 Dec 2033
Type of study
Interventional
Record updated
4 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children aged 12 to 17 years with blood or lymph cancer who are already having intrathecal chemotherapy with MTX at Oslo University Hospital.

Age
12 to 17 years
Sex
Both male and female can join.
Disease stage
Blood or lymph cancer treated with intrathecal chemotherapy with MTX.
Earlier treatment
Must be undergoing intrathecal chemotherapy with MTX for blood or lymph cancer.

Main reasons for not taking part

  • Renal failure
  • Allergy to contrast agents
  • Lowered seizure threshold
  • Pregnancy or breast feeding
  • Body weight not above 50 kg (110 lb)

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age. Participant must be in the age range 12 to 17 years at the time of signing the informed consent
  • Type of Participant and Disease Characteristics. Individuals undergoing intrathecal chemotherapy with MTX for blood or lymph cancer and being treated at Oslo University Hospital
  • Weight. Body weight is above 50 kg
  • Sex and Contraceptive/Barrier Requirements. Both male and female. WOCBP may be included only if they meet protocol pregnancy-testing requirements, have a confirmed menstrual period, have a negative highly sensitive urine or serum pregnancy test before inclusion/intervention, and use highly effective contraception where applicable from inclusion through Day 7 safety follow-up. WOCBP means a post-menarche female participant who is not permanently sterile and not post-menopausal
  • Informed Consent. Documented informed consent/assent must be obtained before any study-specific procedure. Ages 12-15: consent from person(s) with parental responsibility plus age-adapted information and assent/participation according to maturity. Ages 16-17: participant informed consent plus consent from person(s) with parental responsibility. If a participant reaches 18 years before further protocol-defined procedures, express adult informed consent must be obtained

Who cannot take part

  • Medical condition. Renal failure
  • Medical condition. Hypersensitivity/Allergy to contrast agents
  • Medical condition. Lowered seizure threshold
  • Other. Pregnancy or breast feeding

Where in Norway

  • Oslo University Hospital HFOslo, NorwayNot yet recruiting

About the trial

What the trial wants to find out

Investigate/estimate brain fluid clearance (BFC) at the individual level in children aged 12-17 years undergoing clinically indicated intrathecal chemotherapy (methotrexate, and where applicable cytarabine) for blood or lymph cancer.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients
Plain-language title
Measuring Brain Fluid Clearance to Tailor Spinal Chemotherapy in Teens With Leukemia or LymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
4 August 2026